Streetbeat News

PBLA

Panbela Therapeutics Inc.

http://www.sunbiopharma.com/

CEO

Michael Cullen

Open

0.33

Mkt cap

1.7M

Volume

200

High

0.34

P/E Ratio

N/A

52-wk high

38.00

Low

0.33

Div yield

N/A

52-wk low

0.30

Carvana (CVNA) has reached an agreement with noteholders to eliminate over 83% of 2025 and 2027 unsecured note maturities, reducing cash interest expense by over $430M per year for the next two years. Panbela Therapeutics (PBLA) will receive up to $9.5M for divesting assets within its Eflornithine Pediatric Neuroblastoma Program to US WorldMeds. AT&T (T) shares are trading higher after the company confirmed less than 10% of its nationwide copper-wire telecom network has lead-clad cables.

Portfolio Pulse from ryanfaloona@benzinga.com

July 19, 2023 | 12:33 pm

Panbela Therapeutics (NASDAQ:PBLA) has divested certain assets in its eflornithine pediatric neuroblastoma program to US WorldMeds, a Kentucky-based specialty pharmaceutical company. Under the agreement, Panbela is entitled to receive up to approximately $9.5 million non-dilutive funding in exchange for the sale of these assets. Payments will be made upon USWM's successful completion of milestones related to eflornithine's clinical development, regulatory approval, and commercial sales.

Portfolio Pulse from Benzinga Newsdesk

July 19, 2023 | 12:22 pm

Panbela Therapeutics has announced an issue notification for the Australian patent for claims of a novel process for the production of SBP-101. The patent is valid until 2039.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 10:02 am

Panbela Therapeutics Inc's (NASDAQ:PBLA) Phase 3 ASPIRE trial for patients with untreated metastatic pancreatic ductal adenocarcinoma has been recommended to continue without modification by the independent Data Safety Monitoring Board (DSMB). The company is also planning a Phase 1 clinical trial for the second quarter of 2023 to evaluate Ivospemin in treating platinum-resistant ovarian cancer. HC Wainwright maintains a Buy rating and a price target of $16 for PBLA.

Portfolio Pulse from Vandana Singh

July 10, 2023 | 4:55 pm

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Panbela Therapeutics (NASDAQ:PBLA) and maintained a $16 price target.

Portfolio Pulse from Benzinga Newsdesk

July 10, 2023 | 3:20 pm

Panbela Therapeutics, Inc. (NASDAQ:PBLA) announces that the independent Data Safety Monitoring Board (DSMB) of the Phase III ASPIRE clinical trial for patients with untreated metastatic pancreatic ductal adenocarcinoma has recommended that the study continue without modification. The ASPIRE Trial is a global randomized, double-blind placebo-controlled clinical trial to evaluate ivospemin in combination with gemcitabine and nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. The company's pipeline consists of assets currently in clinical trials with an initial focus on familial adenomatous polyposis (FAP), first-line metastatic pancreatic cancer, neoadjuvant pancreatic cancer, colorectal cancer prevention and ovarian cancer.

Portfolio Pulse from Happy Mohamed

July 10, 2023 | 12:17 pm

The article lists the top 5 oversold health care stocks with an RSI near or below 30, which could lead to significant gains in July. The companies mentioned are Cibus, Inc. (CBUS), Panbela Therapeutics, Inc. (PBLA), Vor Biopharma Inc. (VOR), Innovative Eyewear, Inc. (LUCY), and Bellerophon Therapeutics, Inc. (BLPH). All these stocks have seen a recent dip in their prices.

Portfolio Pulse from Lisa Levin

July 05, 2023 | 12:51 pm

Panbela Therapeutics has been granted European Patent Number EP3746425 for its lead investigational product SBP-101, used for the treatment of metastatic pancreatic cancer.

Portfolio Pulse from Happy Mohamed

June 30, 2023 | 4:53 pm

Panbela Therapeutics has announced that its PACES S0820 Phase III trial has passed the pre-planned futility analysis. This is a significant milestone for the company as it indicates that the trial is likely to provide meaningful results.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2023 | 12:16 pm

Panbela Therapeutics announces a poster presentation highlighting the results for CPP-1X in recent onset type 1 diabetes at the Endocrine Society meeting. The research is part of a multi-site clinical trial led by Indiana University School of Medicine, supported by funding from JDRF. Panbela is providing the drug at no cost to researchers.

Portfolio Pulse from Happy Mohamed

June 26, 2023 | 12:22 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.